PT  - JOURNAL ARTICLE
AU  - Lim, ZZ
AU  - Teo, JS
AU  - Tan, AC
AU  - Siam, Tan Soek
AU  - Mohamed, Rosmawati
AU  - Goh, KL
AU  - Jaya, Fauziah
AU  - Senamjit, K
AU  - Aun, Azlida Che’
AU  - Said, Rosaida
AU  - Lim, EK
AU  - Shahar, Hamiza
AU  - Muhammad Radzi, AH
AU  - Poh, Tee Hoi
AU  - Seng, Tan Soon
AU  - Menon, Jayaram
AU  - Menon, Rena
AU  - Lim, TO
TI  - Prevalence of Chronic Hepatitis B and C in Malaysia- results from a community-based screening campaign
AID  - 10.1101/2020.04.30.20085944
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.30.20085944
4099  - http://medrxiv.org/content/early/2020/05/05/2020.04.30.20085944.short
4100  - http://medrxiv.org/content/early/2020/05/05/2020.04.30.20085944.full
AB  - Introduction The epidemiology of hepatitis, which is apparently endemic in Asia, is still poorly documented in Malaysia. Available statistics are modelled estimates based on expert input or estimated from small studies on special populations. We therefore determined the prevalence of chronic hepatitis B and C in Malaysia based on a large sample data from a screening campaign.Methods A total of 10,914 subjects participated in the hepatitis screening campaign in 2018 and 2019. A low-cost Point-of-care test, which has previously been validated, was used to screen for HBsAg and anti-HCV. All screen positive subjects were recalled to undergo confirmatory serology tests and nucleic acid tests.Results We estimated 1.17% or 238,971 Malaysian adults aged 20 or older had chronic HBV, while only 0.74% or 151,144 adults had chronic HCV. Young adults below age 30 years had very low prevalence of HBV (0.09%). Women had lower prevalence of HBV and HCV, Chinese had the highest prevalence of HBV while Malay had the highest prevalence of HCV.Conclusion Young adults seems to be protected from HBV perhaps owing to the introduction of universal HBV vaccination since 1989. Chronic HBV however remains prevalent in older adults especially among the Chinese. Chronic HCV is uncommon in Malaysia.Competing Interest StatementThe authors have declared no competing interest.Clinical Trialthis is NOT a clinical trialFunding StatementThis study is funded by the Hepatitis Free Pahang Malaysia.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used and/or analysed during the current study are available from the corresponding author on reasonable request